Product Information
ZIPRASIDONE HCL 40 MG CAPSULE is a generic product labeled by McKesson, priced at $0.2702 per EA under NDC 63739000532. Its NADAC has been published 526 times since Mar 9, 2016.
FDA first approved this application on Mar 2, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the ziprasidone hydrochloride market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
McKessonNDC
63739000532
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
3/18/2026
Active Ingredients
ZIPRASIDONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077565FDA Approved
3/2/2012
TE Code
AB
On Market Since
3/2/2012
Pharmacological Classes
Price Statistics
The NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has been published 526 times since Mar 9, 2016, and over the history we have for it it has declined 68.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2702 per EA |
|---|---|
| All-time high | $0.8834 (Sep 14, 2016) |
| All-time low | $0.1879 (Nov 20, 2024) |
| 52-week high | $0.2759 |
| 52-week low | $0.2548 |
| Median price | $0.3030 |
| Average price | $0.3743 |
| Largest weekly change | +41.5% (Sep 23, 2020) |
| Weeks tracked | 526 |
| Tracking since | Mar 9, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
+2.9%
3Y
+0.3%
5Y
-9.3%
All
-68.5%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ziprasidone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
McKesson manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ziprasidone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZIPRASIDONE HCL 40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ZIPRASIDONE HCL 40 MG CAPSULE, manufactured by McKesson, is $0.2702 per EA (NDC 63739000532), effective Apr 1, 2026.
How has the price of ZIPRASIDONE HCL 40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has declined 68.5%. It has been tracked across 526 weekly CMS publications since Mar 9, 2016.
What are the highest and lowest recorded NADAC prices for ZIPRASIDONE HCL 40 MG CAPSULE?
Since Mar 9, 2016, the NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has ranged from a low of $0.1879 (Nov 20, 2024) to a high of $0.8834 (Sep 14, 2016), with a median of $0.3030 per EA.
Are there cheaper alternatives to ZIPRASIDONE HCL 40 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ZIPRASIDONE HCL 40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZIPRASIDONE HCL 40 MG CAPSULE?
ZIPRASIDONE HCL 40 MG CAPSULE (NDC 63739000532) is labeled by McKesson, and CMS classifies it as a generic product.